These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35169886)

  • 21. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study.
    Kim N; Min GJ; Im KI; Nam YS; Song Y; Lee JS; Oh EJ; Chung NG; Jeon YW; Lee JW; Cho SG
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease.
    Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P
    Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
    Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
    J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults.
    Wang YM; Teusink-Cross A; Elborai Y; Krupski MC; Nelson AS; Grimley MS; Flannery A; Mehta PA; Bleesing JJ; Chandra S; Kumar AR; Myers KC; Davies SM; Khandelwal P
    Transplantation; 2022 Feb; 106(2):412-419. PubMed ID: 33795598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
    Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G
    Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program.
    Pattipaka T; Sarp S; Nakhaei P; Güneş S
    Bone Marrow Transplant; 2024 May; 59(5):637-646. PubMed ID: 38361117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of ruxolitinib in the salvage treatment of chronic graft versus-host disease].
    Ji YP; Tang BL; Zhu XY; Liu HL; Song KD; Wan X; Yao W; Sun GY; Wang J; Sun ZM
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(16):1235-1239. PubMed ID: 32344495
    [No Abstract]   [Full Text] [Related]  

  • 29. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
    Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
    Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
    Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing.
    Kim D; Taparia M; Robinson E; Mcgee M; Merali T
    Transplant Proc; 2024 Mar; 56(2):409-415. PubMed ID: 38342748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
    Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
    Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
    Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
    Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
    Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R
    Bone Marrow Transplant; 2024 Jun; 59(6):765-776. PubMed ID: 38402346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.
    Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D
    Ann Hematol; 2024 Aug; 103(8):3071-3081. PubMed ID: 38916740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.
    Shahzad M; Chaudhary SG; Basit A; Thellman C; Rodriguez L; Abhyankar SH; McGuirk JP; Mushtaq MU
    Transpl Immunol; 2022 Feb; 70():101520. PubMed ID: 34952168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.